Clinical Trials
48 trialsStudy of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Aulos Bioscience, Inc.
A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer
Cancer Research UK
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
ModeX Therapeutics, An OPKO Health Company
Lead-212 PSV359 Therapy for Patients With Solid Tumors
Perspective Therapeutics
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
AstraZeneca
MTAPESTRY 101
Amgen
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Neonc Technologies, Inc.
Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination
Merus B.V.
A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation
Arvinas Inc.
ODIN
OneCarbon
A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
Takeda
SL-28 for Advanced Solid Tumours
Second Life Therapeutics
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
Ocellaris Pharma, Inc.
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Inhibrx Biosciences, Inc
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
Tanabe Pharma America, Inc.
Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression
BicycleTx Limited
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
LigaChem Biosciences, Inc.
A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors
Bolt Biotherapeutics, Inc.
GLIMMER-01
Palleon Pharmaceuticals, Inc.
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Sensei Biotherapeutics, Inc.
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
NuCana plc
ABILITY-1
Medicenna Therapeutics, Inc.
START-001
Marengo Therapeutics, Inc.
To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors
TransThera Sciences (Nanjing), Inc.
HTL0039732 in Participants With Advanced Solid Tumours
Cancer Research UK
Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy
NGM Biopharmaceuticals, Inc
PRESERVE-001
OncoC4, Inc.
Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
Hutchmed
A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies
Kymab Limited
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
Merus B.V.
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
Aminex Therapeutics, Inc.
A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants with Advanced Unresectable or Metastatic Solid Tumors
NextCure, Inc.
Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
NGM Biopharmaceuticals, Inc
JAVELIN Medley
Pfizer
Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors
Second Affiliated Hospital of Guangzhou Medical University
Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors
TransThera Sciences (Nanjing), Inc.
A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours
Fusion Pharmaceuticals Inc.
Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss
Rain Oncology Inc
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
Klus Pharma Inc.
A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)
Kineta Inc.
REGOMUNE
Institut Bergonié
A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers
Incyte Corporation
INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
Incyte Corporation
Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers
NKGen Biotech, Inc.
PD-1 Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) Associated Malignancies
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid Tumor
National Institutes of Health Clinical Center (CC)